Close Menu

NEW YORK – Interpace Diagnostics, a subsidiary of Interpace Biosciences, has partnered with the University of North Carolina's to explore the use of Interpace's BarreGen test in Barrett's esophagus patients undergoing radiofrequency ablation (RFA), the company announced on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.